Pentwater Capital Management LP Purchases New Shares in Kenvue Inc. $KVUE

Pentwater Capital Management LP acquired a new position in shares of Kenvue Inc. (NYSE:KVUE) during the second quarter, Holdings Channel.com reports. The institutional investor acquired 51,130,000 shares of the company’s stock, valued at approximately $977,094,000. Kenvue makes up about 6.0% of Pentwater Capital Management LP’s investment portfolio, making the stock its 3rd biggest position.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Philadelphia Investment Partners LLC acquired a new position in Kenvue in the 2nd quarter valued at about $259,000. Ausdal Financial Partners Inc. purchased a new position in Kenvue during the 2nd quarter worth approximately $342,000. Bank of America Corp DE purchased a new stake in Kenvue during the 2nd quarter valued at approximately $275,204,000. Port Capital LLC acquired a new stake in Kenvue in the second quarter valued at about $282,000. Finally, Caisse de depot et placement du Quebec acquired a new stake in Kenvue in the 2nd quarter valued at about $16,141,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

KVUE has been the topic of several research analyst reports. UBS Group reduced their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Barclays upped their price objective on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Tuesday, July 21st. Finally, Wall Street Zen downgraded Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Three research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $19.27.

Kenvue Stock Down 0.5%

Shares of NYSE:KVUE opened at $19.23 on Thursday. The company has a 50 day moving average of $19.12 and a 200-day moving average of $18.23. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. The stock has a market cap of $36.94 billion, a price-to-earnings ratio of 22.10, a P/E/G ratio of 1.38 and a beta of 0.47. Kenvue Inc. has a one year low of $14.02 and a one year high of $20.95.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.97 billion. During the same quarter in the prior year, the business earned $0.29 earnings per share. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. On average, sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th were issued a dividend of $0.21 per share. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 12th. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. Kenvue’s dividend payout ratio (DPR) is 96.55%.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.